



Towards targeting cancer therapy; design and synthesis of amide based scaffolds

Thesis Presented by

Eman Mahmoud Elawady Dokla

BSc. in Pharmaceutical Sciences (May 2004)

MSc. in Pharmaceutical Sciences (Pharmaceutical Chemistry) (May 2010)

Assistant Lecturer of Pharmaceutical Chemistry

Ain Shams University

Submitted for the partial fulfilment of the

Doctorate of Philosophy Degree

In Pharmaceutical Sciences (Pharmaceutical Chemistry)

Under the supervision of

Prof. / Khaled A. M. Abouzid

*Professor of Pharmaceutical Chemistry & Vice Dean for the
Educational & Student Affairs
Ain Shams University*

Prof. / Ching-Shih Chen

*Professor of Medicinal Chemistry and Pharmacognosy
The Ohio State University*

Dr. / Nasser S. M. Ismail

*Assistant Professor of Pharmaceutical Chemistry
Ain Shams University*

Dr. / Rabah Ahmed Taha

*Lecturer of Pharmaceutical Chemistry
Ain Shams University*

Faculty of Pharmacy

Ain Shams University

2015

Acknowledgements

It's a pleasure to express my sincere appreciation to **Professor Khaled Abouzid**, Professor of Pharmaceutical Chemistry and Vice Dean for Educational and Student Affairs, for his scientific supervision, innovative ideas, fruitful opinion, invaluable advices and continuous encouragement. I am indebted to him for his guidance and endless support throughout the whole work and during writing this thesis, which allowed this thesis to appear in its final form.

I would like to express my sincere gratitude and thankfulness to **Professor Ching-Shih Chen**, Professor of Medicinal Chemistry and Pharmacognosy, The Ohio State University for giving me the opportunity to join his laboratory for two years. I really appreciate his scientific supervision, wise mentoring, great help, guidance and encouragement.

I owe my truthful gratitude to **Dr. Nasser Saad**, Assistant Professor of Pharmaceutical Chemistry and **Dr. Rabah Taha** Lecturer of Pharmaceutical Chemistry for their continuous encouragement and tremendous support. I am heartily grateful to their indispensable opinion, real interest, trust, caring, eminent guidance and untiring help throughout the whole work.

I am sincerely indebted and thankful to my father, who encouraged me to pursue my dreams, guided me and believed that I can be something when even I doubted myself. He spared no effort, time or money to support and help me establish myself as a researcher.

I acknowledge with thankfulness all my colleagues in Pharmaceutical Chemistry Department, for their friendly cooperation, support and their generous and invaluable aid.

I am also grateful to all Chen's lab members for their help, friendly support and aid.

Finally, I am profoundly indebted to my family for their unconditional love and aid, endless patience, understanding, encouragement and full support all throughout the whole long way.

Contents

Acknowledgements.....	I
Contents.....	II
List of Figures.....	IV
List of Tables.....	VII
List of Abbreviations.....	VIII
Abstract.....	XII
1. Introduction.....	1
1.1. Inside cancer.	1
1.1.1. Overview.	1
1.1.2. Hallmarks of cancer.	1
1.2. Cancer therapy now and then.....	2
1.3. Metabolism reprogramming.	3
1.3.1. Metabolism of quiescent vs. proliferating cells.....	3
1.3.2. The PI3K/Akt/mTOR pathway is a master regulator of aerobic glycolysis and cellular biosynthesis.....	5
1.3.3. Metabolic reprogramming in cancer cells and their mechanism.....	7
1.3.4. Targeting cancer cell metabolism.	10
1.4. AMP activated protein kinase.....	11
1.4.1. AMPK functions and regulation.	11
1.4.2. AMPK and cancer.....	12
1.4.3. Structure of AMPK/activator complex.	13
1.4.4. AMPK, tumor suppressor or promoter?	15
1.4.5. AMPK modulators.....	16
2. Rationale and Design.....	24
2.1. Structural optimization of OSU-53.	25
2.1.1. Identification of key interactions between AMPK $\alpha_2\beta_1$ enzyme allosteric binding site and 991 activator.	25
2.1.2. Docking of OSU-53 into the active site of AMPK $\alpha_2\beta_1$ enzyme.	27

Contents.

2.1.3.	Rational modification of the lead compound, OSU-53	29
2.2.	Schemes for synthesis of the designed compounds.....	32
3.	Results and Discussion.....	39
3.1.	Chemistry.....	39
3.2.	Biological Evaluation.....	57
3.2.1.	Antiproliferative activity.....	57
3.2.2.	Western blot analysis of AMPK phosphorylation.....	65
3.2.3.	Mechanistic investigation of the effects of 81 , 89 , and 101 on AMPK signaling. 68	
3.2.4.	<i>In Vivo</i> Efficacy of 89 versus OSU-53 in Suppressing PC-3 Xenograft Tumor Growth.70	
3.3.	Molecular modeling.....	73
	Field Alignment.....	73
4.	Final Conclusion.....	75
5.	Experimental.....	76
5.1.	Chemistry.....	76
5.1.1.	Materials and Methods.....	76
5.1.2.	Synthesis.....	77
5.2.	Biological evaluation.....	124
5.2.1.	Cell lines, culture, reagents and antibodies.....	124
5.2.2.	Cell viability assay.....	124
5.2.3.	Cell lysis and immunoblotting.....	125
5.2.4.	Testing of <i>in vivo</i> efficacy of OSU-53 and 89 in PC-3 tumor-bearing nude mice. 125	
5.2.5.	Statistical analysis.....	126
5.3.	Molecular modeling study.....	127
5.3.1.	Docking analysis.....	127
5.3.2.	Field Alignment.....	127
6.	Supplementary Data.....	128
	Spectroscopic, HPLC retention times and purity data of compounds involved in SAR. ..	128
7.	References.....	200

List of Figures

Figure 1. Therapeutic targeting of the hallmarks of cancer ⁴	3
Figure 2. Metabolism of quiescent cells versus proliferative cells ⁹	4
Figure 3. Metabolic pathways active in proliferating cells. Key metabolic pathways are labeled in purple with white boxes, and the enzymes controlling critical steps in these pathways are shown in blue ⁹	6
Figure 4. Signaling and transcriptional machinery that regulate metabolism, various components of the signaling and transcriptional network can genetically behave as oncogenes (red) or tumor suppressors (green) ²⁶	7
Figure 5. As a result of oncogenic gain-of-function events (pink) or the loss of tumor suppressors (green) affecting the PI3K/Akt/mTOR/HIF axis and/or inactivation of the p53 system, a stereotyped pattern of metabolic changes is induced, leading to cancer-associated alterations in metabolism ³³	10
Figure 6. Small molecules targeting the PI3K/Akt/mTORC pathway. Inhibitors and activators are in red. Inhibitors for both mTORC1 and mTORC2 are highlighted in yellow. Dual inhibitors for PI3K and mTORC1 and mTORC2 are highlighted in blue ³⁵	11
Figure 7. Function and regulation of AMPK leading to tumor suppression. LKB1 is the upstream kinase activating AMPK in response to AMP or ADP increase, whereas CAMKK2 activates AMPK in response to calcium increase ³⁹	12
Figure 8. A full-length human AMPK α 2 β 1 γ 1 enzyme bound to activator 991 . Kinase domain is depicted in orange while the CBM is depicted in green ⁵⁷	14
Figure 9. Schematic representation for the regulation of AMPK by kinase domain and CBM interacting with the regulatory fragment. Regulatory fragment (R) containing the γ -subunit (in pink) and the C-termini domains of the α - and β -subunits (in light blue/green). The α 2 kinase domain (phosphorylated on Thr-172 of the activation loop) is shown in yellow and is connected to the regulatory fragment by a flexible linker (in black). The CBM of the β -subunit (colored in green) binds to the N-lobe of the kinase domain and is also connected to the regulatory fragment by a flexible linker (in black) ⁵⁷	15
Figure 10. Detailed view of 991 binding at the allosteric binding site. (A) The hydrophobic residues from the kinase (yellow) and CBM (green) are shown as sticks with surfaces. (B) Salt bridges are shown as heavy dotted line, hydrogen bonds as light dotted line and cation- π stacking as hashed line ⁵⁷	26
Figure 11. 2D interaction diagram of 991 inside the allosteric binding site of human AMPK enzyme (4CFE), hydrophobic amino acid are colored in green while polar ones are colored in purple.	26
Figure 12. 3D interaction diagram of compound (OSU-53) inside the allosteric binding site of human AMPK α 2 β 1 enzyme (PDB code: 4CFE). Hydrogen bonds are represented by red dotted line, π -cation interactions are depicted by black dashed line & the amino acids involved in hydrophobic interactions are represented as thin yellow wire.	27

List of Figures.

Figure 13. 2D interaction diagram of OSU-53 inside the allosteric binding site of human AMPK enzyme (4CFE), hydrophobic amino acid are colored in green while polar ones are colored in purple.	28
Figure 14. Overlapped docking poses of crystallized ligand 991 and OSU-53 , shows similar binding mode.	28
Figure 15. General structural optimization strategy of OSU-53	29
Figure 16. Surface representation of the allosteric binding site of human AMPK $\alpha_2\beta_1$ enzyme (PDB code: 4CFE), shows a large hydrophobic channel lined by hydrophobic amino acid residues and hydrophobic side chains, 89 (orange color) and OSU-53 (blue color).	30
Figure 17. 3D interaction diagram of 89 inside the allosteric binding site of human AMPK $\alpha_2\beta_1$ enzyme (PDB code: 4CFE). Hydrogen bonds are represented by red dotted line, π -cation interactions are depicted by black dashed line & the amino acids involved in hydrophobic interactions are represented as thin yellow wire.	31
Figure 18. General mechanism of trifluoromethyl acetylation using organolithium reagent.	41
Figure 19. Equilibrium between trifluoromethyl ketone derivatives and their corresponding hydrates.	42
Figure 20. Mechanism of oxidation of sulfides to sulfoxides utilizing <i>m</i> -CPBA.	43
Figure 21. Mitsunobu reaction mechanism.	49
Figure 22. A schematic diagram illustrating the strategies used for the lead optimization of OSU-53	57
Figure 23. Western blot analysis of dose-dependent effects of metformin (left) and AICAR (right).	65
Figure 24. Western blot analysis of the effects of selected derivatives, each at 2.5 μ M, on AMPK phosphorylation in MDA-MB-231 cells after 48 h of treatment.	66
Figure 25. Time and dose-dependent suppressive effects of 81 , 89 , and 101 versus OSU-53 on the viability of MDA-MB-231 cells, as determined by MTT assays. Data are presented as means \pm S.D. (<i>n</i> = 6).	67
Figure 26. Western blot analysis of the dose-dependent effects of individual agents at on the phosphorylation of AMPK and downstream targets, including ACC, p70S6K, and Akt in MDA-MB-231 cells after 48 h of exposure.	68
Figure 27. Western blot analysis of the effect of compound 89 versus OSU-53 on the phosphorylation of AMPK, ACC, p70S6K, and Akt in MDA-MB468 and PC-3 cells after 48 h of treatment.	69
Figure 28. Western blot analysis of the suppressive effect of 89 on EMT in MDA-MB-231 and PC-3 cells, as manifested by increases in the expression of Foxo3a and the epithelial marker claudin-1 or E-cadherin, accompanied by parallel decreases in the expression of the mesenchymal markers vimentin and snail.	70
Figure 29. (A) In vivo efficacy of 89 versus OSU-53 in suppressing PC-3 xenograft tumor growth. Athymic nude mice bearing established subcutaneous PC-3 xenograft tumors were treated once daily with vehicle, OSU-53 , or 89 via oral gavage at 50 mg/kg for 28 days. Tumor volume (left) and body weight (right) data are presented as means \pm S.E. (<i>n</i> = 7). (B) Western	

List of Figures.

<i>blot analysis of the phosphorylation of AMPK, ACC, and Akt in lysates from four representative tumors from each group of mice after 28 days of treatment.</i>	<i>71</i>
Figure 30. <i>Structural similarities and differences between compound 81 and the reported AMPK activator 991.</i>	<i>73</i>
Figure 31. <i>Field alignment of compound 81 and the reported AMPK activator 991 showing similar molecular fields between the 4-chloro-3-nitrophenyl and benzylidene urea of 81 and ring 3 and 2 of 991. Compound 81 extends further due to the 3,5-diCF₃ phenyl substitution.</i>	<i>74</i>

List of Tables

Table 1. Metabolic Effects of Selected Oncogenes and Tumor Suppressor Genes ³³	8
Table 2. Cytotoxicity data of Series A (32-66) on MDA-MB-231 cells after 72 h exposure using MTT assays.	59
Table 3. Cytotoxicity data of Series B (67-70) on MDA-MB-231 cells after 72 h exposure using MTT assays.	61
Table 4. Cytotoxicity data of Series C (71, 72) on MDA-MB-231 cells after 72 h exposure using MTT assays.	61
Table 5. Cytotoxicity data of Series D (73 – 80) on MDA-MB-231 cells after 72 h exposure using MTT assays.	62
Table 6. Cytotoxicity data of Series E (81 – 108) on MDA-MB-231 cells after 72 h exposure using MTT assays.	62
Table 7. Cytotoxicity data of Series F (109 – 114) on MDA-MB-231 cells after 72 h exposure using MTT assays.	64
Table 8. Cytotoxicity data of Series G (115, 116) on MDA-MB-231 cells after 72 h exposure using MTT assays.	64
Table 9. HPLC Retention Times and Purity Data for biologically tested compounds:.....	128

List of Abbreviations

ACC: Acetyl-CoA carboxylase

ACL: ATP citrate lyase

AIBN: Azobisisobutyronitrile

AICAR: 5'-aminoimidazole- 4-carboxamide ribonucleoside

Akt: Protein kinase B (Pkb)

AMP: Adenosine monophosphate

AMPK: Adenosine monophosphate activated protein kinase

Borane-DMS complex: Borane-dimethylsulfide complex

CA: Carbonic anhydrase

CAMKK2: Calcium/calmodulin-dependent protein kinase kinase 2

CBM: Carbohydrate binding module

ChoK: Choline Kinase

c-Myc: a regulator gene that codes for a transcription factor

COX-2: Cyclooxygenase-2

CPT1A: Carnitine palmitoyltransferase 1A

Dabco: 1,4-diazabicyclo[2.2.2]octane

DCM: Dichloromethane

DEAD: Diethyl azodicarboxylate

DIAD: Diisopropyl azodicarboxylate

DIBAL-H: Diisobutylaluminium hydride

List of Abbreviations.

DIPEA: Diisopropylethylamine

DIPEA: *N,N*-Diisopropylethylamine

DMAP: 4-Dimethylaminopyridine

DMF: Dimethylformamide

DMP: Dess–Martin periodinane

EMT: Epithelial-mesenchymal transition

ETFA: Ethyl trifluoroacetate

EtOAc: Ethyl acetate

EtOH: Ethanol

FASN: Fatty acid synthase

FH: Fumarate hydratase (fumarase)

GAPDH: Glyceraldehyde 3-phosphate dehydrogenase

GLUT1: Glucose transporter 1

GLUT4: Glucose transporter 4

Her2: human epidermal growth factor receptor 2

HIF1 α : hypoxia inducible factor 1 α

HK: Hexokinase

IGFIR: Insulin-like growth factor receptor

IR: Insulin receptor

LDHA: Lactate dehydrogenase A

LKB1: Liver kinase B1

mCPBA: m-chloroperoxybenzoic acid

List of Abbreviations.

MCT4: Monocarboxylate transporter 4

mTOR: Mammalian target of rapamycin

mTORC1: mTOR complex 1

MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide

NADPH: Reduced form of nicotinamide adenine dinucleotide phosphate

NBS: N-bromosuccinimide

NF1: Neurofibromin 1

NHE1: Sodium/hydrogen exchanger 1

NMP: *N*-Methyl-2-pyrrolidone

OXPHOS: Oxidative phosphorylation

p53: Tumor protein p53

p70S6K: Serine/Threonine kinase

PCC: Pyridinium chlorochromate

PDB: Protein Data Bank

PDC: Pyridinium dichromate

PDHs: Prolyl hydroxylases

PDK: Pyruvate dehydrogenase kinase

PFK: Phosphofructokinase

PGM: Phosphoglycerate mutase

PI3K: Phosphoinositide 3-kinase

PIP3: Phosphatidylinositol (3,4,5)-trisphosphate

PKM2: Pyruvate kinase isoform M2

List of Abbreviations.

PML: Probable transcription factor

PPP: Pentose phosphate pathway

PRAS40: Proline-rich Akt substrate of 40kDa

PTEN: Phosphatase and tensin homolog

RAPTOR: Regulatory-associated protein of mTOR

RAS: Class of protein called small GTPase and are involved in transmitting signals within cells

Rheb: Ras homolog enriched in brain

ROS: Reactive oxygen species

RTK: Receptor tyrosine kinase

SCO2: Cytochrome c oxidase assembly protein

SDHB, C and D: Succinate dehydrogenase subunits B, C and D

SREBP-1: Sterol regulatory element-binding protein 1

STK11: Serine/threonine kinase 11 (LKB1)

TBAB: Tetrabutylammonium bromide

TCA cycle: Tricarboxylic acid cycle

TEA-HCl: Triethylamine hydrochloride salt

TIGAR: TP53-inducible glycolysis and apoptosis regulator

TSC1: Tuberous sclerosis complex 1 (hamartin)

TSC2: Tuberous sclerosis complex 2 (tuberin)

ULK: Unc-51-like kinase

VDAC: Voltage dependent anion channel

VHL: Von Hippel–Lindau tumor suppressor

Abstract.

Title of thesis:

Towards targeting cancer therapy; design and synthesis of amide based scaffolds

Name of candidate:

Eman Mahmoud Elawady Dokla

Assistant Lecturer of Pharmaceutical Chemistry

Ain Shams University

Under the supervision of:

Prof. / Khaled A. M. Abouzid

Prof. / Ching-Shih Chen

Dr. / Nasser S. M. Ismail

Dr. / Rabah Ahmed Taha

Abstract

Cancer is a generic term for a large group of diseases that can affect any part of the body. One defining feature of cancer is the rapid creation of abnormal cells that grow beyond their usual boundaries, and which can then invade adjacent parts of the body and spread to other organs, the latter process is referred to as metastasizing. Metastases are the major cause of death from cancer. Cancer is among the leading causes of death worldwide. In 2012, there were 14 million new cases and 8.2 million cancer-related deaths worldwide. The number of new cancer cases will rise to 22 million within the next two decades. More than 60% of the world's new cancer cases occur in Africa, Asia, and Central and South America; 70% of the world's cancer deaths also occur in these regions.

Knowledge about the causes of cancer, and interventions to prevent and manage the disease is extensive. Cancer can be reduced and controlled by implementing evidence-based strategies for cancer prevention, early detection of cancer and management of patients with cancer. Many cancers have a high chance of cure if detected early and treated adequately.

Adenosine monophosphate-activated protein kinase (AMPK) is a key player in maintaining energy homeostasis in response to metabolic stress. Beyond diabetes and metabolic syndrome, there is a growing interest in the therapeutic exploitation of the AMPK pathway in cancer treatment in light of its unique ability to regulate cancer cell proliferation through the reprogramming of cell metabolism.

Previously, a novel thiazolidinedione-based AMPK activator (**OSU-53**) was identified, which provided a proof-of-concept to highlight the important role of AMPK in regulating oncogenic signaling pathways associated with cell proliferation and epithelial-mesenchymal transition (EMT) in cancer cells. In this study, we used **OSU-53** as a scaffold to conduct lead optimization, which generated a library of eighty five derivatives. The design process focused on Identification of key interactions between AMPK α 2 β 1 enzyme allosteric binding site and the reported activator **991**, modeling studies including docking of **OSU-53** into the active site of AMPK α 2 β 1 enzyme and finally rational modification of the lead compound, **OSU-53** guided by modeling studies to help establish a clear SAR for this class of compounds.

Abstract.

Synthesis of the designed compounds was then accomplished & their structures were confirmed by various spectral and HPLC purity data.

This study involved the synthesis of the following unavailable reported intermediates:

- 1) *3-(Bromomethyl)benzamide (3a)*
- 2) *4-(Bromomethyl)benzamide (3b)*
- 3) *4-(Bromomethyl)benzenesulfonamide (6)*
- 4) *3-(Trifluoroacetyl)benzyl bromide (9a)*
- 5) *4-(Trifluoroacetyl)benzyl bromide (9b)*
- 6) *4-(Methylsulfinyl)benzyl bromide (11a)*
- 7) *4-(Trifluoromethyl sulfinyl)benzyl bromide (11b)*
- 8) *4- Isopropoxy benzyl alcohol (13a)*
- 9) *3,4-Bis(trifluoromethyl)benzyl alcohol (13b)*
- 10) *2-Chloro-4-nitrobenzaldehyde (17a)*
- 11) *2-(Trifluoromethyl)-4-nitrobenzaldehyde (17b)*
- 12) *2-Methoxy-4-nitrobenzaldehyde (17c)*
- 13) *3-Chloro-4-nitrobenzaldehyde (17d)*
- 14) *3-(Trifluoromethyl)-4-nitrobenzaldehyde (17e)*
- 15) *3-Methoxy-4-nitrobenzaldehyde (17f)*
- 16) *4-Methoxy-3-nitrophenyl isothiocyanate (19a)*
- 17) *3-Isothiocyanato benzenesulfonamide (19b)*
- 18) *5-(4-Nitrobenzylidene)-1,3-thiazolidine-2,4-dione (26)*
- 19) *3-[[4-(Trifluoromethyl)phenyl]methyl]-5-(4-nitrobenzylidene)-1,3-thiazolidine-2,4-dione (27g)*
- 20) *3-[[4-Bromophenyl]methyl]-5-(4-nitrobenzylidene)-1,3-thiazolidine-2,4-dione (27j)*
- 21) *3-[[4-Tert-butylphenyl]methyl]-5-(4-nitrobenzylidene)-1,3-thiazolidine-2,4-dione (27m)*
- 22) *3-[[4-Methoxyphenyl]methyl]-1,3-thiazolidine-2,4-dione (28a)*
- 23) *3-[[3,5-Bis(trifluoromethyl)phenyl]methyl]-1,3-thiazolidine-2,4-dione (28e)*
- 24) *3-[[4-(Trifluoromethyl)phenyl]methyl]-5-(4-aminobenzylidene)-1,3-thiazolidine-2,4-dione (30g)*